Clinical Trial


A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion


Brief description

This is a Phase 2, open label, multicenter, study evaluating the efficacy and safety of ABT-199 (Venetoclax) in relapsed or refractory subjects with CLL harboring 17p13 (TP53 locus) deletion. One hundred seven (107) subjects were enrolled in the main cohort, with evaluation of efficacy as the primary objective, and approximately 50 subjects will be enrolled in the safety expansion cohort to evaluate safety and updated tumor lysis syndrome prophylaxis and management measures. Enrollment into the main cohort is closed. Enrollment into the safety expansion cohort is closed.

Keywords

  •   Chronic Lymphocytic Leukemia
  •   17 p Deletion
  •   Cancer of the Blood and Bone Marrow

Sponsored By

AbbVie

Unique Study ID

NCT01889186

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Purdue Pharma LP
85704, Tucson, Arizona, United States
Distance from Current Trial is 0 miles

No Investigator Listed

Purdue Pharma LP
85712, Tucson, Arizona, United States
Distance from Current Trial is 0 miles

No Investigator Listed

Purdue Pharma LP
85704, Tucson, Arizona, United States
Distance from Current Trial is 0 miles
View All